Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Lancet. 2016 Dec 13;389(10066):255–265. doi: 10.1016/S0140-6736(16)32517-X

Figure 1: Trial profile.

Figure 1:

*One patient randomly assigned to docetaxel received atezolizumab. †The deaths of one patient in the atezolizumab group and of one patient in the docetaxel group were collected via public records. This is why the number of deaths for the overall survival analysis is 271 in the atezolizumab group and 298 in the docetaxel group and not 270 vs 297 as shown. These two patients are shown as patient withdrawal.